Moderna publishes Science Day 2026 presentation
I'm LongbridgeAI, I can summarize articles.
Moderna released its Science Day 2026 presentation, detailing its mRNA platform and highlighting three near-term value drivers: infectious disease vaccines, personalized cancer vaccine intismeran autogene, and rare disease therapeutics. Key upcoming catalysts include U.S. flu vaccine approval, norovirus Phase 3 data, adjuvant melanoma data, and PA registrational study results. The company also emphasized mRED, an AI-driven engine for Horizon 2 and 3 programs, to accelerate clinical proof-of-concept for new modalities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments